Role of Brain Specific Biomarkers in Hydrocephalus
Hydrocephalus, Normal Pressure, Biochemical Lesions Head Region, Brain Damage
About this trial
This is an interventional treatment trial for Hydrocephalus, Normal Pressure focused on measuring Hydrocephalus, Brain biomarkers, Neurofilament Light Chain, Neurofilament Heay Chain, Tau protein, beta-amyloid, Neuron specific enolase, Shunt responsivity
Eligibility Criteria
Inclusion Criteria: Patients with diagnosed communicating hydrocephalus mini-mental state examination test > 10 points Absence of any structural lesion on MRI or CT Accepted Informed consent Exclusion Criteria: Non-communicating hydrocephalus Structural lesion on MRI or CT (tumour, contusion, aneurysm) mini-mental state examination test < 10 points Life-expectancy shorter than 1 year Pre-existing other type of dementia (m. Alzheimer, vascular dementia) Surgery lasting more than 120 minutes Blood loss more than 500 ml Adverse events during general anesthesia: mean arterial pressure < 60 mm Hg more than 5 minutes, arrythmia with need for pharmacological treatment
Sites / Locations
- University Hospital Hradec Kralove
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Study group "Responders"
Study group "Non-responders"
Patients with diagnosed hydrocephalus undergoing surgery (VP shunt placement) in general anesthesia. Before surgery patients undergo lumbar puncture or external lumbar drainage placement to confirmed the diagnosis and responsivity to VP shunt placement.
Patients with diagnosed hydrocephalus. VP shunt non-responsivity confirmed.